Join our daily newsletter At The Bell to receive exclusive market insights
- ResApp Health (RAP) locks in a three-year licensing agreement with Janssen Pharmaceutica NV for use of its ResAppDx technology in a trial
- The study will see ResAppDx used by Janssen to assess the respiratory symptoms of a group of patients with a range of respiratory diseases
- Janssen will pay development and maintenance costs, in addition to a fee for each ResAppDx test used
- The trial is set to be conducted across the US, Europe, South America, and Asia Pacific later this year
- ResApp shares last traded at 5.3 cents on November 17
ResApp Health (RAP) has locked in a three-year licensing agreement for use of its ResAppDx technology in a respiratory syncytial virus clinical trial.
ResAppDx is a diagnostic test that uses machine-learning technology to analyse cough sounds to diagnose respiratory disease using a smartphone’s inbuilt microphone.
The digital health company secured the non-exclusive agreement with Janssen Pharmaceutica NV, one of the pharmaceutical companies of Johnson & Johnson, for use of its technology to study respiratory syncytial virus (RSV).
The trial will see ResAppDx used by Janssen to assess the respiratory symptoms of a group of patients with a range of respiratory diseases, including RSV. This marks the first time ResAppDx has ever been used by a third party to monitor patients in a clinical trial setting.
RSV is a virus that causes respiratory infections, like inflammation of the small breathing tubes of the lung and pneumonia. Severe cases of the illness can spread to the lower respiratory tract, causing chronic obstructive pulmonary disease or asthma. The company noted almost 160,000 people die each year as a result of RSV.
Janssen will pay development and maintenance costs, in addition to a fee for each ResAppDx test used.
“With this agreement, we are demonstrating that leading global pharmaceutical companies see the value of ResAppDx in a clinical trial setting,” ResApp Health CEO and Managing Director Tony Keating said.
“While not expected to have a material impact on our operating results at this stage, this contract represents the beginning of our commercial relationship with Janssen and will further build the body of high quality, clinical evidence regarding the use of ResAppDx.”
The trial is set to be conducted across the US, Europe, South America and the Asia Pacific later this year.
ResApp shares last traded at 5.3 cents on November 17.
